Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858552 | 1.00 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL21726069 | 0.93 | P2RY12 (0.55) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL21263848 | 0.91 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL24322092 | 0.90 | P2RY12 (0.43) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL25293 | 0.90 | P2RY12 (0.48) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL20692061 | 0.89 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL19146239 | 0.88 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6CYP1A2 | |
| SCHEMBL21540034 | 0.87 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL20353076 | 0.86 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL23621388 | 0.86 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-01-07 | — | — | US | disclosed |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | Aduro Biotech, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, NTPCR | P2RY12 1249/4885P2RY2 985/4885P2RY1 762/4885 |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | STING1, IRF3, CGAS | P2RY12 73/4885P2RY2 24/4885P2RY1 23/4885 |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | P2RY12 81/4885P2RY2 18/4885P2RY1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.